Paired Immunoglobulin-like Type 2 Receptor Alpha G78R variant alters ligand binding and confers protection to Alzheimer's disease

Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA) is a cell surface inhibitory receptor that recognizes specific O-glycosylated proteins and is expressed on various innate immune cell types including microglia. We show here that a common missense variant (G78R, rs1859788) of PILRA is the like...

Full description

Saved in:
Bibliographic Details
Published inPLoS genetics Vol. 14; no. 11; p. e1007427
Main Authors Rathore, Nisha, Ramani, Sree Ranjani, Pantua, Homer, Payandeh, Jian, Bhangale, Tushar, Wuster, Arthur, Kapoor, Manav, Sun, Yonglian, Kapadia, Sharookh B, Gonzalez, Lino, Zarrin, Ali A, Goate, Alison, Hansen, David V, Behrens, Timothy W, Graham, Robert R
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 02.11.2018
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Paired Immunoglobulin-like Type 2 Receptor Alpha (PILRA) is a cell surface inhibitory receptor that recognizes specific O-glycosylated proteins and is expressed on various innate immune cell types including microglia. We show here that a common missense variant (G78R, rs1859788) of PILRA is the likely causal allele for the confirmed Alzheimer's disease risk locus at 7q21 (rs1476679). The G78R variant alters the interaction of residues essential for sialic acid engagement, resulting in >50% reduced binding for several PILRA ligands including a novel ligand, complement component 4A, and herpes simplex virus 1 (HSV-1) glycoprotein B. PILRA is an entry receptor for HSV-1 via glycoprotein B, and macrophages derived from R78 homozygous donors showed significantly decreased levels of HSV-1 infection at several multiplicities of infection compared to homozygous G78 macrophages. We propose that PILRA G78R protects individuals from Alzheimer's disease risk via reduced inhibitory signaling in microglia and reduced microglial infection during HSV-1 recurrence.
Bibliography:new_version
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current address: Therapeutics, 23 and Me, South San Francisco, California, United States of America
Current address: Department of Antibody engineering, Genentech Inc., South San Francisco, California, United States of America
NR, SRR, HP, JP, TB, AW, YS, SBK, LG, AAZ, DVH, TWB and RRG were full-time employees at Genentech while the work was conducted. A patent has been submitted for this work.
ISSN:1553-7404
1553-7390
1553-7404
DOI:10.1371/journal.pgen.1007427